drugset
drugset / Trial / NCT05824143

Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult Participants

NCT05824143 ↗

Phase 1 Completed 13 enrolled Cerevel Therapeutics, LLC
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of the study is to evaluate the effect of increased metabolizing enzyme (cytochrome P450 \[CYP\] 3A4) due to carbamazepine, a strong CYP3A4 inducer, on the pharmacokinetics (PK) of darigabat in healthy adult participants.

Timeline

Start
2023-04-17
Primary completion
2023-07-07
Completion
2023-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule — Oral
Subject Darigabat Small molecule — Oral

Indications

No indication recorded.